Skip to main content

What We Do

MTRC has been providing reimbursement, health economic and evidence synthesis services to the medical device and in-vitro diagnostics industry in Europe since 2017. 

Coding, payment mechanism, reimbursement tariffs, policy and HTA considerations

Pathways to establish reimbursement, funding and obtain endorsement in the HTA programs

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Essential tool to support market access and marketing efforts through the lifecycle of the product

Early and comprehensive decision-analytic models to determine economic value proposition and inform healthcare decision-makers

News and insights

To stay up to date, we constantly monitor developments of reimbursement systems in Europe

Subscribe to our newsletter to get bi-weekly updates key reimbursement/HTA news items

Subscribe Subscribe Subscribe Subscribe Subscribe Subscribe

Our free newsletter contains less than 10% of the identified news items. Access our paid service Market Access Monitor to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). 

06 Nov 2024

Meet MTRC at the ISPOR meeting in Barcelona, 18-20 of November 2024

The MTRC team, including Director Oleg Borisenko and Reimbursement Leads, will be attending the ISPOR meeting in Barcelona on 18-20 November 2024. Visit us at booth #829 to discuss your needs in European market access, health economics, and evidence synthesis for medical technologies.
06 Nov 2024

Multiple changes in the Prenatal Testing Program in Poland

In late October 2024, the Agency for Health Technology Assessment and Tariff System (AOTMiT) published several recommendations concerning the Prenatal Testing Program, specifically on removing alpha-fetoprotein and estriol testing and qualifying the placental growth factor (PlGF) test and free fetal DNA testing (cffDNA) as part of non-invasive prenatal diagnostics.
05 Nov 2024

Preliminary 2025 Norwegian DRG system released

In October 2024, the Norwegian Directorate of Health published a preliminary version of the DRG system (Innsatsstyrt finansiering, ISF) for 2025. Two new DRGs concerning men’s health and dental areas will be introduced.

Geography of our projects

MTRC is a provider of multi-country European projects. We have worked on the projects in 34 European countries

 

MTRC in numbers 

An extremely specialised boutique consultancy with a global impact

19
19
Full-time employees
893
893
Projects
221
221
Clients
17
17
Regular clients from the top 30 med tech companies
12%
12%
Of business comes from Small to Medium-sized Enterprises (SMEs)

Why partner with MTRC?

Be confident in the results

We are accredited by the United Kingdom Accreditation Service (UKAS) as an ISO 9001:2015 certified vendor, specialised in medical technologies market access. Unlike many of our competitors, we dedicate 100% of our time and focus to the area of medical technologies, so that our clients enjoy higher quality services at a lower cost. We are also probably the largest Med Tech market access consultancy in Europe, which helps us accumulate unique knowledge and insight

Avoid the hassle of working with multiple vendors

We specialize in Pan-European projects and worked in 34 countries in Europe. You can save time, effort and money by working with a single experienced vendor vs contracting several consultants individually

Spend less on consulting

We understand the budgetary challenges of the med tech industry and can therefore offer a cost-effective approach to our specialised services. Twelve percent (12%) of our current business comes from small to medium-sized enterprises (SMEs) – a testament to our unique and personal approach to solve your budgetary challenges

Direct access to senior leadership

Small enough to ensure significant personal attention, and large enough to address your needs, our boutique consultancy guarantees that each project enjoys the attention it deserves with direct access to our senior leaders

Make decisions and advance your business quickly

We appreciate the time-sensitive nature of market access. Being a flexible team, we are not afraid to go beyond regular working hours to meet the high expectations of our clients. For every type of project, we offer the shortest possible turnaround times

Technological coverage of our services

We provide services for major types of medical technologies:

Implantable devices
Interventional procedures
Non-interventional procedures
In-Vitro diagnostics (IVD) tests
Medical aids

Our team has worked on hundreds of reimbursement/HEOR projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, and endoscopy, amongst others.

Testimonials from our clients

Since 2017, we have accomplished more than 880 projects for more than 220 companies. The quality of our work translates into building long-term relationships with our clients: 78% of the business comes from repeat clients, and our Net Promoter Score (NPS) is 10 out of 10. While most of the projects are performed under strict NDAs, we are still delighted to share testimonials from some of our clients, representing both large corporations and start-ups. 

“MTRC is an expert in the market access of medical devices. They are updated about changes and know the realities that impact the business. They are fair and honest with their advice and trustworthy with discussions and deliverables. It is a pleasure to work with MTRC, whom we consider a reliable partner.“
Zenichi Ihara, Director, Health Economics and Reimbursement EMEA, CRM, EP, HF, Abbott
“MTRC takes time to fully understand our questions and objectives and delivers insightful, professional, and valuable results accordingly.”
Michael Morseon, Senior Director, Healthcare Economics & Market Access, Cooper Surgical
“Oleg and the team at MTRC provided us with a very comprehensive analysis with key sights and recommendations for a practical and feasible reimbursement approach for our product. MTRC took the time to understand our clinical area and brought clinical consultants on board during the activity for an in-depth understanding of our field of work. I recommend MTRC to my peers and the institutions we are affiliated with.”
Sarusha Pillay, Commercial Lead, pHetalSafe (pre-spinout team) at the University College Cork
“I have used the services of MTRC a number of times in different positions during my career and have found them to be a leading authority on Health Technology Assessment and Reimbursement marketing research, even for the most obscure of clinical case types. They are fast, efficient, transparent, professional, and the quality of their reporting is second to none. I highly recommend them as a research firm on anything reimbursement or HTA related for the European Continent.”
Michael van Driel, Vice President Global Business Development and General Manager, CBM Lifemotion
“Working with MTRC was a great experience. Their expertise and professionalism were evident in every step of the project. The team was highly responsive and delivered clear and timely results. I highly recommend MTRC for any project that requires a clear reimbursement strategy and local reimbursement analysis.”
Itay Jacob, VP Sales & Marketing, Mego Afek
“I’ve just completed my 2nd experience of collaboration with MTRC, both on the MedTech and Pharma reimbursement environment. I have come back to MTRC because of the speed of execution (compared to other vendors), the acumen in the preparatory work, and the accuracy of the report. I also very much value their insights on policy recommendations, helping me to navigate very complex reimbursement systems at the EU level. Definitely recommended!”
Andrea Minotto, Director Global Market Access, Bracco
“MTRC, led by Oleg Borisenko and his team, has been an invaluable partner to InVera Medical over the past several years. Their expertise in European reimbursement, market analysis, and budget impact assessments has consistently provided us with high-quality insights that have been crucial for our strategic decisions. The team's clear communication, reliability, and ability to deliver on time have made them a trusted consultant in our journey. We highly recommend MTRC for their exceptional service and expertise.”
Stephen Cox, CEO, Co-Founder, InVera Medical
"MTRC exceeded our expectations for our university medical device technology. Beyond delivering expert reimbursement analysis and market access strategies for our target geographies, they proactively identified additional optimal markets we hadn't considered. Their team's accessibility and patience in explaining complex analyses made them true partners in our project's development. For anyone seeking thorough, strategic market access guidance, MTRC is an outstanding choice."
Justina Ugwah, Commercial lead, CLISTEPROBE, Tyndall National Institute
"Invizius is a clinical-stage biotech developing second-generation complement therapies addressing serious unmet needs for patients on extracorporeal circuit therapies. For our company to be successful, it is important to develop reimbursement solutions and market access strategies to allow for fast and widespread adoption of our breakthrough technology. MTRC provided us with a clear market access reimbursement strategy specifically designed around the specificities and patient benefits of our lead product H-Guard. This individualized approach is unique among consultants and has proven invaluable. We would highly recommend MTRC for anyone seeking advice on European market access."
Eric Beard, Chairman, Invizius

Thought Leadership

Market Access Monitor

Service of monitoring key reimbursement and HTA developments for medical devices, in-vitro diagnostic tests, and digital technologies in Europe and globally.

Learn more

Free EU reimbursement news and Publications Digest

Bi-weekly newsletter with 10 key reimbursement/HTA news items and summaries of the most important peer-reviewed publications. Access news from as far back as 2017. 

Learn more

Analytical White Papers

Free analytical and research White Papers on the topic of reimbursement, HTA and evidence requirements for medical devices and IVD tests in Europe.

Learn more

Knowledge Zone

Brief summaries of the market access landscape for medical technologies and in-vitro diagnostic tests in European countries.

Learn more

Knowledge Zone – Technologies

Brief summaries of the market access landscape and challenges for individual types of medical technologies in Europe

Learn more

Report on innovative payment schemes for EU association Med Tech Europe

In 2022 Med Tech Europe and MTRC developed a comprehensive report on innovative payment schemes in European countries.

Learn more

Educational materials on market access

MTRC offers the most comprehensive repository of training presentations on the topic of med tech market access. We offer both general introductory seminars (including pre-recorded webinars) and more than 70 country-specific seminars. 

Learn more

Youtube channel “Market Access Insider”

In 2019 MTRC launched a channel dedicated to the topic of market access for medical devices. See our interviews with different stakeholders from EU countries.

Learn more

Get in touch

Contact us to discuss your needs and learn about our services